Holen Sie sich die Stockscreener-App
8.99
1.24%
0.11
Vorhandelsmarkt:
8.71
-0.28
-3.11%
Schlusskurs vom Vortag:
$8.88
Offen:
$9.03
24-Stunden-Volumen:
107.49K
Relative Volume:
1.50
Marktkapitalisierung:
$467.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.32M
KGV:
-14.50
EPS:
-0.62
Netto-Cashflow:
$-36.14M
1W Leistung:
+9.77%
1M Leistung:
+31.24%
6M Leistung:
-18.64%
1J Leistung:
+53.68%
1-Tages-Spanne:
$8.5901
$9.33
1-Wochen-Bereich:
$8.25
$9.33
52-Wochen-Spanne:
$5.67
$14.99
Gh Research Plc Stock (GHRS) Company Profile
Vergleichen Sie GHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
8.99 | 467.73M | 0 | -32.32M | -36.14M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-16 | Eingeleitet | ROTH Capital | Buy |
Gh Research Plc Aktie (GHRS) Neueste Nachrichten
GH Research PLC (NASDAQ:GHRS) Sees Large Increase in Short Interest - MarketBeat
How the (GHRS) price action is used to our Advantage - Stock Traders Daily
GH Research (NASDAQ:GHRS) Earns “Buy” Rating from HC Wainwright - Defense World
Cormark Issues Negative Outlook for Hudbay Minerals Earnings - Defense World
What is Zacks Research’s Forecast for HALO Q3 Earnings? - Defense World
Equities Analysts Offer Predictions for APOG FY2025 Earnings - Defense World
Jane Street Group LLC Cuts Stock Holdings in Columbia Research Enhanced Value ETF (NYSEARCA:REVS) - Defense World
Harmonic (NASDAQ:HLIT) Rating Lowered to Equal Weight at Barclays - Defense World
Medican Enterprises (OTCMKTS:MDCN) Shares Cross Above Fifty Day Moving Average – Should You Sell? - Defense World
Digital Turbine (NASDAQ:APPS) Shares Cross Above 50 Day Moving Average – Should You Sell? - Defense World
Barclays PLC Purchases Shares of 3,960 American Outdoor Brands, Inc. (NASDAQ:AOUT) - Defense World
Barclays PLC Purchases New Shares in Innovator U.S. Equity Buffer ETF – March (BATS:BMAR) - Defense World
Barclays PLC Invests $40,000 in FT Vest U.S. Equity Deep Buffer ETF – July (BATS:DJUL) - Defense World
Barclays PLC Invests $35,000 in VTEX (NYSE:VTEX) - Defense World
Barclays PLC Purchases 37,347 Shares of MarketWise, Inc. (NASDAQ:MKTW) - Defense World
Barclays PLC Has $39,000 Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
11,475 Shares in NeoVolta Inc. (NASDAQ:NEOV) Acquired by Barclays PLC - Defense World
Barclays PLC Takes Position in Myomo, Inc. (NYSEAMERICAN:MYO) - Defense World
American Realty Investors, Inc. (NYSE:ARL) Shares Bought by Barclays PLC - Defense World
Barclays PLC Increases Stock Holdings in Angi Inc. (NASDAQ:ANGI) - Defense World
ProShares UltraPro QQQ (NASDAQ:TQQQ) Shares Sold by Barclays PLC - Defense World
GH Research reports progress in depression treatment trials By Investing.com - Investing.com Australia
GH Research (NASDAQ:GHRS) Earns "Buy" Rating from HC Wainwright - MarketBeat
GH Research says completed all FDA requests to address IND hold - TipRanks
GH Research reports progress in depression treatment trials - Investing.com India
GH Research announces primary endpoint met in two Phase 2a PoC trials - TipRanks
GH Research Achieves Key Milestones in Depression Trials and Prepares FDA Response - TipRanks
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents - The Manila Times
GH Research Announces Primary Endpoint Met in Two Phase 2a - GlobeNewswire
GH Research's Depression Drug Achieves 100% Remission in Postpartum Trial, Advances in Bipolar Study - StockTitan
Cedi To End 2025 Around GH¢17.70 To Dollar – Report - Peace FM Online
Learn to Evaluate (GHRS) using the Charts - Stock Traders Daily
Credibility gap closing for psychedelics - BioWorld Online
GH Research (NASDAQ:GHRS) Trading Down 6.7% – Should You Sell? - Defense World
GH Research (NASDAQ:GHRS) Shares Down 6.7%Should You Sell? - MarketBeat
How To Trade (GHRS) - Stock Traders Daily
CBG secures historic GH¢350m capital raise for Kasapreko PLC - Myjoyonline
Fmr LLC Boosts Stake in Vodafone Group Public Limited (NASDAQ:VOD) - Defense World
Fmr LLC Trims Holdings in GH Research PLC (NASDAQ:GHRS) - MarketBeat
3 Top Cybersecurity Stock Picks for 2025 - Head Topics
GH Research PLC Attends Key Neuropsychopharmacology Conference - TipRanks
RA Capital Management L.P. Has $44.73 Million Stock Position in GH Research PLC (NASDAQ:GHRS) - MarketBeat
GH Research PLC (NASDAQ:GHRS) Shares Sold by Verition Fund Management LLC - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Down 0.3%What's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 2%Should You Buy? - MarketBeat
GH Research (NASDAQ:GHRS) Trading Down 0.8%Here's What Happened - MarketBeat
(PDF) Neurotrophic and synaptic effects of GnRH and/or GH upon motor function after spinal cord injury in rats - ResearchGate
GH Research (NASDAQ:GHRS) Stock Price Up 1.4%Here's Why - MarketBeat
GH Research’s (GHRS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
(GHRS) Technical Data - Stock Traders Daily
HC Wainwright Reduces Earnings Estimates for GH Research - Defense World
Finanzdaten der Gh Research Plc-Aktie (GHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):